Back

Natco Pharma Gets US FDA EIR for Its Visakhapatnam Plant

The US FDA classified the August 2026 inspection of Natco Pharma's Parawada, Visakhapatnam formulations facility as Voluntary Action Indicated.

Natco Pharma Visakhapatnam EIR: the Natco Pharma logo on a pharmaceutical manufacturing scene

Key Takeaways

  • Natco Pharma received a US FDA EIR for its Parawada, Visakhapatnam FDF facility.
  • The US FDA classified the inspection as Voluntary Action Indicated (VAI).
  • The inspection ran from August 17 to August 21, 2026.
  • It ended with a Form 483 carrying four observations.
  • Natco disclosed the EIR to the stock exchanges on November 20, 2026.
Table of Contents 5 sections
  1. Natco Pharma's Visakhapatnam EIR at a glance
  2. How the August inspection led to a VAI rating for Natco's Vizag plant
  3. Natco's US FDA inspections at its Visakhapatnam formulations facility
  4. Where Natco Pharma's Visakhapatnam plant stands after the EIR
  5. FAQs

Natco Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Finished Dosage Formulations (FDF) manufacturing facility at Parawada, Visakhapatnam, in Andhra Pradesh. The Hyderabad-based drug maker told the stock exchanges about it on November 20, 2026.

The EIR covers a US FDA inspection of the plant held from August 17 to August 21, 2026. That inspection ended with a Form 483 carrying four observations, which Natco disclosed on August 21. The US FDA has now classified the inspection as Voluntary Action Indicated (VAI), which means the regulator found conditions that call for voluntary corrective action by the company.

Natco Pharma's Visakhapatnam EIR at a glance

DetailValue
CompanyNatco Pharma Ltd
FacilityFinished Dosage Formulations (FDF) manufacturing facility
LocationParawada, Visakhapatnam, Andhra Pradesh
Inspection datesAugust 17 to August 21, 2026
Form 483 observationsFour
ClassificationVoluntary Action Indicated (VAI)
Disclosed to exchangesNovember 20, 2026

How the August inspection led to a VAI rating for Natco's Vizag plant

When the August inspection ended, Natco said it believed the four observations were procedural in nature and that it was confident of addressing them within the stipulated timelines. The EIR now received from the US FDA communicates the VAI classification for that inspection.

Natco is headquartered in Hyderabad. The company says its facilities are approved by regulators including the US FDA, Brazil's ANVISA, Health Canada and the WHO, and that it serves more than 50 global markets.

Natco's US FDA inspections at its Visakhapatnam formulations facility

WhenWhat happened
March 24 to March 30, 2020US FDA inspected Natco's drug formulations facility at Visakhapatnam
May 2020Natco received an EIR for that inspection
January 30 to February 3, 2023US FDA inspection ended with two observations, one on written production process control procedure and one on investigation procedure
June 2023Natco received an EIR closing the 2023 inspection
August 17 to August 21, 2026US FDA inspected the Parawada FDF facility and issued a Form 483 with four observations
November 20, 2026Natco disclosed the EIR with a VAI classification

Where Natco Pharma's Visakhapatnam plant stands after the EIR

Natco Pharma's Parawada, Visakhapatnam FDF facility now has an EIR from the US FDA, with the August 2026 inspection classified as Voluntary Action Indicated. The inspection had ended with four Form 483 observations, which the company said it believed were procedural in nature. Natco had earlier received EIRs for its drug formulations facility at Visakhapatnam in May 2020 and June 2023.

More news

Join Us Add as preferred source
Share

Frequently Asked Questions

What is Natco Pharma?

Natco Pharma is a Hyderabad-headquartered drug maker whose facilities are approved by regulators including the US FDA, Brazil's ANVISA, Health Canada and the WHO.

What did Natco Pharma receive from the US FDA?

Natco Pharma received an Establishment Inspection Report (EIR) from the US FDA for its FDF manufacturing facility at Parawada, Visakhapatnam.

Which Natco Pharma facility does the EIR cover?

The EIR covers Natco Pharma's Finished Dosage Formulations (FDF) manufacturing facility at Parawada, Visakhapatnam, in Andhra Pradesh.

When was Natco Pharma's Visakhapatnam facility inspected?

The US FDA inspected Natco Pharma's Parawada, Visakhapatnam facility from August 17 to August 21, 2026.

How many observations did Natco Pharma get in the inspection?

Natco Pharma received a Form 483 with four observations at the end of the August 2026 inspection.

How did the US FDA classify Natco Pharma's inspection?

The US FDA classified the inspection of Natco Pharma's Visakhapatnam facility as Voluntary Action Indicated (VAI).

What does the VAI classification mean for Natco Pharma?

VAI means the US FDA found conditions at Natco Pharma's facility that call for voluntary corrective action by the company.

When did Natco Pharma disclose the EIR?

Natco Pharma disclosed the EIR for its Visakhapatnam facility to the stock exchanges on November 20, 2026.

How did Natco Pharma describe the four observations?

After the inspection in August, Natco Pharma said it believed the four observations were procedural in nature.

When did Natco Pharma receive earlier EIRs for Visakhapatnam?

Natco Pharma received earlier US FDA EIRs for its drug formulations facility at Visakhapatnam in May 2020 and June 2023.

How many observations did Natco Pharma get in the 2023 inspection?

The 2023 US FDA inspection of Natco Pharma's Visakhapatnam formulations facility ended with two observations.

How many markets does Natco Pharma serve?

Natco Pharma says it serves more than 50 global markets.

More in Business